Exchange: OTC·Updated 09:49 AM EDT

About PATLF

About

Patrys Ltd. engages in the commercialization of the group's proprietary technologies to develop natural human antibody-based therapeutic products for the treatment of cancer and the pursuit of non-dilutive funding sources. Its pipeline includes PAT-DX1 antibody fragment, PAT-DX3 full sized antibody, and PAT-DX1-NP conjugated to nanoparticles. The company was founded by Daniel Devine on December 8, 2006 and is headquartered in Nedlands, Australia.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A

Frequently Asked Questions

Advertisement|Remove ads.